The state of New York currently has 3 active clinical trials seeking participants for Diabetic Macular Edema research studies. These trials are conducted in various cities, including New York, Rochester, Bronx and Buffalo.
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
Recruiting
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be ente... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Liverpool, NY, Liverpool, New York +2 locations
Conditions: Diabetic Macular Edema (DME)
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
Recruiting
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Retina Vitreous Surgeons of Central NY, PC, Liverpool, New York +1 locations
Conditions: Diabetic Macular Edema (DME)
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Recruiting
This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications. The aim of the study is to see how safe and effective aflibercept HD injections are when given as frequently as every 4 weeks. The study is also looking at what side effects may happen from taking the study drug.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Vitreoretinal Consultants of NY, Westbury, New York
Conditions: Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema